If approved, Ascendis’ TransCon CNP would become the second therapy for achondroplasia, challenging BioMarin’s Voxzogo.
FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study ...
Investor's Business Daily on MSN
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam ...
NMC and ICMR to launch PhD programme soon, boost clinical research: Dr Abhijat ShethVadodara: Aiming to promote indigenous ...
BridgeBio Pharma (BBIO), a mid-cap biotech company, has investors thrilled with its commercial engine scaling following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback